Researchers tested a novel five-session therapy combining trauma-focused writing with cannabis coping skills in three young women following recent sexual assault. All participants showed reduced PTSD symptoms and cannabis use, but because there was no comparison group and natural recovery is common in this population, the therapy’s specific contribution remains unknown.

In the weeks following sexual assault, many survivors develop intertwined PTSD symptoms and escalating cannabis use, each reinforcing the other in a cycle that current treatment approaches rarely address simultaneously. There is no validated brief integrated intervention for this specific co-occurrence in the acute post-assault window. The clinical stakes are high: untreated PTSD and problematic cannabis use in the first weeks after assault may predict chronic trajectories that become harder to interrupt with time. Understanding whether early, integrated treatment can break this cycle is one of the most pressing unanswered questions in trauma-informed substance use care.

Co-occurring PTSD and cannabis use disorder following sexual assault represent a common clinical challenge, with each condition capable of maintaining and worsening the other. Cannabis is frequently used as self-medication for trauma-related hyperarousal and insomnia, yet chronic cannabis use may interfere with natural fear extinction processes and complicate standard PTSD treatments. Written Exposure Therapy, or WET, is a brief trauma-focused protocol with growing evidence of non-inferiority to Prolonged Exposure in broader PTSD populations. STEPS adapts WET by integrating cognitive-behavioral coping skills specifically targeting cannabis use, delivered in just five sessions within weeks of sexual assault. The rationale is that addressing both conditions simultaneously during the acute post-trauma window may prevent chronic entrenchment of either disorder.

All three participants demonstrated reductions in both PTSD symptom severity, as measured by the gold-standard CAPS-5 clinical interview and the PCL-5 self-report, and in past-month cannabis use at post-treatment and one-month follow-up. The authors report that reductions met thresholds generally considered clinically meaningful on standardized instruments. However, no statistical testing was performed, and the sample size of three precludes any reliable effect size estimation. Critically, the study employed no control or comparison condition, and the literature on post-assault PTSD trajectories shows that natural recovery is the norm rather than the exception: roughly 75% of survivors meet PTSD criteria at one month, but only about 42% do at twelve months. The authors appropriately characterize these findings as preliminary and call for randomized controlled trials.

Brief Integrated Therapy for PTSD and Cannabis Use Disorder After Rape: What Three Cases Can and Cannot Tell Us

In the weeks following a sexual assault, many survivors face a cruel double bind: trauma symptoms drive cannabis use, and cannabis use may worsen trauma symptoms. A new brief therapy called STEPS sets out to break this cycle, but how much can we conclude from three cases? The answer requires separating what this paper actually tested from what it appears to claim. The authors designed and delivered a five-session integrated protocol combining written trauma exposure with cannabis-specific coping skills to three young women in the acute aftermath of rape. All three improved. The paper frames this appropriately as a feasibility demonstration and preliminary observation. What it genuinely contributes is valuable: a clearly described, rationally constructed intervention targeting a real gap in the clinical literature, documented proof that recruitment through forensic nursing contacts is achievable, and measurement conducted with the gold-standard CAPS-5 interview by reliability-checked assessors. These are the hallmarks of a well-run early-stage study. The trouble lies in the gap between what the data show and what the data can mean. Three participants improved in an uncontrolled design, in a population where improvement without treatment is not merely possible but expected. Giving a patient with a common cold a new remedy and reporting they feel better a week later tells us almost nothing about the remedy itself, because colds resolve on their own. We need to compare to people who had the same cold and received no remedy. The same logic applies here, and it applies with particular force: published longitudinal data indicate that the majority of sexual assault survivors who meet PTSD criteria shortly after the assault will no longer meet criteria months later, with or without any formal treatment.

The central methodological issue is therefore not complexity but clarity. Without a comparison group, the study cannot distinguish the effect of STEPS from spontaneous recovery, nonspecific therapeutic contact, regression to the mean, or the simple passage of time. This is not a minor caveat. It is the structural limitation that defines what the evidence can and cannot support. To a patient, I would say this: the therapy is based on sound principles, and it was tolerable and associated with improvement in the initial group studied, but we do not yet have the kind of evidence that tells us it specifically caused those improvements beyond what time and support alone provide. To a colleague, I would frame it differently: the protocol is ready for a controlled trial, and the recruitment pathway works, but we should not mistake encouraging descriptive data for a confirmed signal. And to a policymaker, my message would be direct: this research deserves funding for a rigorous randomized trial, not implementation dollars. We have a real public health need, a promising protocol, and a documented pathway to participants. What we lack is the controlled comparison that separates hope from evidence.

STEPS represents a thoughtfully constructed and feasibly delivered early intervention for an underserved clinical problem. The three women in this case series showed reductions in PTSD symptoms and cannabis use, findings that are encouraging, appropriately reported as preliminary, and consistent with the existing literature on both integrated treatment and Written Exposure Therapy. But they are equally consistent with natural recovery, therapeutic contact, and regression to the mean in a population selected at a symptom peak. The most important contribution of this paper is not its outcome numbers but its protocol documentation and its proof that recruitment and delivery in the acute post-assault period is achievable. The distance between a promising case series and a proven treatment is almost always longer and harder than the initial data suggest. In populations with high natural recovery rates, an uncontrolled design is particularly vulnerable to false optimism.

This case series sits at the earliest stage of the clinical research arc: proof-of-concept and feasibility. It follows a growing body of work adapting Written Exposure Therapy to substance-using populations, including studies in residential treatment settings and among pregnant women with co-occurring substance use disorders. The broader integrated PTSD and substance use disorder treatment literature, including recent individual patient data meta-analyses, supports the general principle that integrated treatments are at least as effective as sequential ones and carry additional practical advantages. STEPS builds on these foundations while addressing a specific population and a specific substance that have been understudied.

From a pharmacological and safety standpoint, clinicians should note that cannabis use in the acute post-trauma period may have complex bidirectional effects on PTSD symptom trajectories. Some observational data suggest cannabis may temporarily reduce hyperarousal symptoms while potentially interfering with fear extinction and consolidation processes central to trauma recovery. The safety profile of STEPS itself cannot be meaningfully characterized from three cases, though no serious adverse events were reported. The inclusion of safety planning for suicidality is an appropriate protocol feature given the elevated risk in this population. The single most actionable recommendation for clinicians at this stage is to monitor this intervention as it moves toward controlled testing, and to avoid interpreting this case series as sufficient grounds for adopting STEPS over established, better-validated treatments for PTSD or cannabis use disorder.

This is an uncontrolled, open-label case series with three participants, representing the lowest tier of clinical evidence in the hierarchy of study designs. Case series are valuable for documenting novel procedures, identifying feasibility, and generating hypotheses, but they cannot establish causation, estimate effect sizes reliably, or support generalization. The single most important inference constraint is the absence of any comparison condition, which makes it impossible to attribute observed improvements to the intervention rather than to the passage of time, natural recovery, or nonspecific therapeutic factors.

This study extends but does not contradict the existing evidence base. Written Exposure Therapy has been tested in randomized trials against Prolonged Exposure for PTSD, with results supporting non-inferiority in broader trauma populations (Sloan et al., 2023). Integrated PTSD and substance use disorder treatments have been supported by meta-analytic evidence showing they are at least comparably effective to sequential approaches (Hill et al., 2024; Hien et al., 2023). What STEPS adds is the novel combination of WET with cannabis-specific coping skills in the acute post-assault period, a specific configuration not previously tested. However, the finding that all three participants improved is fully consistent with the well-documented natural recovery trajectories reported in longitudinal post-sexual assault cohorts (Dworkin et al., 2023), making it difficult to determine whether STEPS contributes incremental benefit beyond what time and standard support provide.

The most consequential analytic choice in this study is not a statistical one but a structural one: the decision to report outcomes without any comparison condition. Had the researchers included even a small waitlist control or a treatment-as-usual group, the same outcome data could have been interpreted with substantially greater confidence. In a population where natural recovery rates are high, the inclusion of a concurrent comparison group is the single design choice that would most dramatically alter the interpretability of results. Within the case series format itself, alternative analysis approaches such as single-case experimental designs with repeated baselines or within-subject phase comparisons could have strengthened causal inference modestly, though practical and ethical considerations in this acute post-trauma population make such designs challenging.

The most likely overinterpretation is that STEPS has been shown to reduce PTSD and cannabis use after sexual assault. This exceeds what the evidence supports because the study had no comparison group and only three participants. In a population where the majority of individuals naturally experience substantial symptom reduction in the months following assault, finding that all three treated participants improved is exactly what one would expect even without any intervention. The result is consistent with a treatment effect, but it is equally consistent with spontaneous recovery, regression to the mean, or the nonspecific benefits of therapeutic attention. A related misreading is to conclude that the treatment has been demonstrated as safe; three uneventful completions do not constitute a safety profile.

This case series contributes a clearly described novel intervention protocol, demonstrates that recruitment and treatment delivery in the acute post-sexual assault period is feasible, and provides preliminary descriptive outcome data. It does not establish whether STEPS causes improvements in PTSD or cannabis use beyond natural recovery. For clinical practice, this study generates a hypothesis worth testing in a controlled trial but does not provide evidence sufficient to change current treatment approaches for co-occurring PTSD and cannabis use disorder.

Does this study prove that STEPS therapy works for PTSD and cannabis use after sexual assault?

No. The study included only three people and had no comparison group, so we cannot distinguish whether the improvements seen were caused by the therapy or by the natural healing that commonly occurs in the weeks and months after sexual assault. The findings are encouraging enough to justify further testing, but they do not constitute proof of efficacy.

Is it common for PTSD symptoms to improve on their own after sexual assault?

Yes. Research shows that while approximately 75% of sexual assault survivors meet criteria for PTSD in the first month, that number drops to roughly 42% by twelve months without any specific treatment. This natural recovery pattern is the primary reason why a case series without a control group cannot tell us whether any particular therapy is responsible for improvement.

If I am a survivor dealing with both PTSD and cannabis use, should I seek out STEPS therapy specifically?

STEPS is not yet widely available and has not been tested in a controlled trial. If you are experiencing PTSD and problematic cannabis use, the most evidence-supported step is to seek help from a mental health professional experienced in trauma-informed care. Several established therapies for PTSD, including Prolonged Exposure, Cognitive Processing Therapy, and Written Exposure Therapy, have stronger evidence bases. Discuss your cannabis use openly with your provider so treatment can address both concerns.

Does cannabis help or hurt PTSD recovery?

The relationship between cannabis and PTSD is complex and not fully understood. Some individuals report temporary relief from hyperarousal, anxiety, and insomnia, but there is concern that regular cannabis use may interfere with the brain’s natural fear-processing mechanisms that are central to trauma recovery. The current evidence does not support cannabis as a treatment for PTSD, and emerging data suggest problematic cannabis use may complicate recovery trajectories.

Have thoughts on this? Share it: